Abstract
The current study examined three pressor systems which might support mean arterial pressure (MAP) after lesions of the rostral ventrolateral medulla (RVLM). In two protocols, bilateral electrolytic lesions or sham lesions were placed in the RVLM of rats anesthetized with sodium pentobarbital. In the first protocol, the following drugs were given sequentially after placement of the lesions: captopril (5 mg/kg) and d-pentamethylene methylated tyrosine (30 μg/kg), a vascular arginine-vasopressin antagonist (AVPX). A final procedure consisted of spinal-cord transection. The second protocol was identical to the first except that the order of drug administration was reversed. In the first protocol, RVLM lesions caused a slight, but statistically significant, decrease in MAP from 118 ± 3 mmHg to 103 ± 5 mmHg. After captopril and AVPX, MAP further decreased to 87 ± 5 mmHg and 62 ± 4 mmHg, respectively. The MAP fell to 38 ± 2 mmHg after spinal-cord transection. In the sham-lesion group, MAP rose slightly from 127 ± 6 mmHg to 134 ± 7 mmHg after placement of the sham lesions. A significant reduction in MAP was not seen until after administration of AVPX, which decreased MAP to 103 ± 6 mmHg. Spinal-cord transection substantially lowered MAP to 36 ± 4 mmHg. In the second protocol, RVLM lesions had no effect on MAP. Administration of AVPX had little effect on MAP (before:117 ± 5 mmHg; after:102 ± 7 mmHg). In contrast, sequential administration of captopril substantially decreased MAP to 55 ± 5 mmHg. Spinal cord transection lowered MAP to 33 ± 1 mmHg. A decrease in MAP in the companion sham-lesion group was not seen until after administration of captopril (before:109 ± 8 mmHg; after: 89 ± 11 mmHg). The greatest fall in MAP followed spinal cord transection (to 39 ± 6 mmHg). These results demonstrate normotension after RVLM lesions despite a marked reduction in sympathetic vasomotor activity. They also indicate that, after RVLM lesions, arterial pressure is maintained mainly by activity of the renin-angiotensin system and by AVP secretion.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.